The erythropoietin and regenerative medicine: a lesson from fish

Background  Erythropoietin (EPO), the main haematopoietic growth factor for the proliferation and differentiation of erythroid progenitor cells, is also known for its angiogenic and regenerative properties. Materials and methods  In this study, we aimed to test the regenerative effects of EPO admini...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical investigation 2009-11, Vol.39 (11), p.993-999
Main Authors: Buemi, M., Lacquaniti, A., Bolignano, D., Maricchiolo, G., Favaloro, A., Buemi, A., Grasso, G., Donato, V., Giorgianni, G., Genovese, L., Coppolino, G., Sfacteria, A.
Format: Article
Language:English
Subjects:
Angiogenesis
Animals
Bass
Biological and medical sciences
erythropoietin
Erythropoietin - genetics
Erythropoietin - metabolism
fin growth
Fishes
General aspects
Immunohistochemistry
Medical sciences
Models, Biological
Neovascularization, Physiologic - genetics
Neovascularization, Physiologic - physiology
regeneration
Regeneration - genetics
Regeneration - physiology
Regenerative Medicine
sea bass
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background  Erythropoietin (EPO), the main haematopoietic growth factor for the proliferation and differentiation of erythroid progenitor cells, is also known for its angiogenic and regenerative properties. Materials and methods  In this study, we aimed to test the regenerative effects of EPO administration in an experimental model of Sea bass (Dicentrarchus labrax) subjected to amputation of the caudal fin. Results  Erythropoietin‐treated fishes (3000 UI of human recombinant EPO‐alpha immediately after cutting and after 15 days) showed an increased growth rate of their fins compared with those untreated (anova variance: P: 0·01 vs. P: 0·04). By analysing fin length at established times (15 and 30 days after cut), EPO‐treated fishes always showed an increased length compared with untreated ones (T‐15: 1·1 ± 0·2 vs. 0·7 ± 0·2 cm, P: 0·03; T‐30: 1·9 ± 0·3 vs. 1·2 ± 0·2 cm, P: 0·01). Moreover, exogenous EPO administration induced an enormous increase in EPO‐blood levels at each observation time (T‐15: 2240 ± 210 vs. 16·7 ± 1·8 mU mL−1, P 
ISSN:0014-2972
1365-2362
DOI:10.1111/j.1365-2362.2009.02197.x